Selected research
Industry Research
PCSK9 Antagonists Industry Research Report 2026
Market perspective
The global PCSK9 Antagonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for PCSK9 Antagonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for PCSK9 Antagonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of PCSK9 Antagonists include Amgen, Merck, Novartis, Regeneron Pharmaceuticals, Sanofi, Hasten Biopharmaceutical, Jiangsu Hengrui Pharmaceuticals, Junshi Biosciences and Akeso, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global PCSK9 Antagonists market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
PCSK9 Antagonists Market by Company
Amgen
Merck
Novartis
Regeneron Pharmaceuticals
Sanofi
Hasten Biopharmaceutical
Jiangsu Hengrui Pharmaceuticals
Junshi Biosciences
Akeso
Innovent Biologics
Salubris Pharmaceuticals
PCSK9 Antagonists Segment by Type
Monoclonal Antibody
siRNA
Other
PCSK9 Antagonists Segment by Application
Atherosclerotic Cardiovascular Disease
Hypercholesterolemia
Others
PCSK9 Antagonists Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PCSK9 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PCSK9 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PCSK9 Antagonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of PCSK9 Antagonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of PCSK9 Antagonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of PCSK9 Antagonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal Antibody
- siRNA
- Other
Applications
- Atherosclerotic Cardiovascular Disease
- Hypercholesterolemia
- Others
Companies covered
- Amgen
- Merck
- Novartis
- Regeneron Pharmaceuticals
- Sanofi
- Hasten Biopharmaceutical
- Jiangsu Hengrui Pharmaceuticals
- Junshi Biosciences
- Akeso
- Innovent Biologics
- Salubris Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global PCSK9 Antagonists Market Size (2021-2032)
- 2.2.2 Global PCSK9 Antagonists Sales (2021-2032)
- 2.2.3 Global PCSK9 Antagonists Market Average Price (2021-2032)
- 2.3 PCSK9 Antagonists by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Monoclonal Antibody
- 2.3.3 siRNA
- 2.3.4 Other
- 2.4 PCSK9 Antagonists by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Atherosclerotic Cardiovascular Disease
- 2.4.3 Hypercholesterolemia
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global PCSK9 Antagonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global PCSK9 Antagonists Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global PCSK9 Antagonists Revenue of Manufacturers (2021-2026)
- 3.4 Global PCSK9 Antagonists Average Price by Manufacturers (2021-2026)
- 3.5 Global PCSK9 Antagonists Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of PCSK9 Antagonists, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of PCSK9 Antagonists, Product Type & Application
- 3.8 Global Manufacturers of PCSK9 Antagonists, Established Date
- 3.9 Global PCSK9 Antagonists Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Amgen
- 4.1.1 Amgen Company Information
- 4.1.2 Amgen Business Overview
- 4.1.3 Amgen PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Amgen PCSK9 Antagonists Product Portfolio
- 4.1.5 Amgen Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck PCSK9 Antagonists Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis PCSK9 Antagonists Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Regeneron Pharmaceuticals
- 4.4.1 Regeneron Pharmaceuticals Company Information
- 4.4.2 Regeneron Pharmaceuticals Business Overview
- 4.4.3 Regeneron Pharmaceuticals PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Regeneron Pharmaceuticals PCSK9 Antagonists Product Portfolio
- 4.4.5 Regeneron Pharmaceuticals Recent Developments
- 4.5 Sanofi
- 4.5.1 Sanofi Company Information
- 4.5.2 Sanofi Business Overview
- 4.5.3 Sanofi PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sanofi PCSK9 Antagonists Product Portfolio
- 4.5.5 Sanofi Recent Developments
- 4.6 Hasten Biopharmaceutical
- 4.6.1 Hasten Biopharmaceutical Company Information
- 4.6.2 Hasten Biopharmaceutical Business Overview
- 4.6.3 Hasten Biopharmaceutical PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hasten Biopharmaceutical PCSK9 Antagonists Product Portfolio
- 4.6.5 Hasten Biopharmaceutical Recent Developments
- 4.7 Jiangsu Hengrui Pharmaceuticals
- 4.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 4.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 4.7.3 Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Product Portfolio
- 4.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 4.8 Junshi Biosciences
- 4.8.1 Junshi Biosciences Company Information
- 4.8.2 Junshi Biosciences Business Overview
- 4.8.3 Junshi Biosciences PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Junshi Biosciences PCSK9 Antagonists Product Portfolio
- 4.8.5 Junshi Biosciences Recent Developments
- 4.9 Akeso
- 4.9.1 Akeso Company Information
- 4.9.2 Akeso Business Overview
- 4.9.3 Akeso PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Akeso PCSK9 Antagonists Product Portfolio
- 4.9.5 Akeso Recent Developments
- 4.10 Innovent Biologics
- 4.10.1 Innovent Biologics Company Information
- 4.10.2 Innovent Biologics Business Overview
- 4.10.3 Innovent Biologics PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Innovent Biologics PCSK9 Antagonists Product Portfolio
- 4.10.5 Innovent Biologics Recent Developments
- 4.11 Salubris Pharmaceuticals
- 4.11.1 Salubris Pharmaceuticals Company Information
- 4.11.2 Salubris Pharmaceuticals Business Overview
- 4.11.3 Salubris Pharmaceuticals PCSK9 Antagonists Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Salubris Pharmaceuticals PCSK9 Antagonists Product Portfolio
- 4.11.5 Salubris Pharmaceuticals Recent Developments
5 Global PCSK9 Antagonists Market Scenario by Region
- 5.1 Global PCSK9 Antagonists Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global PCSK9 Antagonists Sales by Region: 2021-2032
- 5.2.1 Global PCSK9 Antagonists Sales by Region: 2021-2026
- 5.2.2 Global PCSK9 Antagonists Sales by Region: 2027-2032
- 5.3 Global PCSK9 Antagonists Revenue by Region: 2021-2032
- 5.3.1 Global PCSK9 Antagonists Revenue by Region: 2021-2026
- 5.3.2 Global PCSK9 Antagonists Revenue by Region: 2027-2032
- 5.4 North America PCSK9 Antagonists Market Facts & Figures by Country
- 5.4.1 North America PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America PCSK9 Antagonists Sales by Country (2021-2032)
- 5.4.3 North America PCSK9 Antagonists Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe PCSK9 Antagonists Market Facts & Figures by Country
- 5.5.1 Europe PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe PCSK9 Antagonists Sales by Country (2021-2032)
- 5.5.3 Europe PCSK9 Antagonists Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific PCSK9 Antagonists Market Facts & Figures by Country
- 5.6.1 Asia Pacific PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific PCSK9 Antagonists Sales by Country (2021-2032)
- 5.6.3 Asia Pacific PCSK9 Antagonists Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America PCSK9 Antagonists Market Facts & Figures by Country
- 5.7.1 South America PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America PCSK9 Antagonists Sales by Country (2021-2032)
- 5.7.3 South America PCSK9 Antagonists Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa PCSK9 Antagonists Market Facts & Figures by Country
- 5.8.1 Middle East and Africa PCSK9 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa PCSK9 Antagonists Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa PCSK9 Antagonists Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global PCSK9 Antagonists Sales by Type (2021-2032)
- 6.1.1 Global PCSK9 Antagonists Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global PCSK9 Antagonists Sales Market Share by Type (2021-2032)
- 6.2 Global PCSK9 Antagonists Revenue by Type (2021-2032)
- 6.2.1 Global PCSK9 Antagonists Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global PCSK9 Antagonists Revenue Market Share by Type (2021-2032)
- 6.3 Global PCSK9 Antagonists Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global PCSK9 Antagonists Sales by Application (2021-2032)
- 7.1.1 Global PCSK9 Antagonists Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global PCSK9 Antagonists Sales Market Share by Application (2021-2032)
- 7.2 Global PCSK9 Antagonists Revenue by Application (2021-2032)
- 7.2.1 Global PCSK9 Antagonists Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global PCSK9 Antagonists Revenue Market Share by Application (2021-2032)
- 7.3 Global PCSK9 Antagonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 PCSK9 Antagonists Value Chain Analysis
- 8.1.1 PCSK9 Antagonists Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 PCSK9 Antagonists Production Mode & Process
- 8.2 PCSK9 Antagonists Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 PCSK9 Antagonists Distributors
- 8.2.3 PCSK9 Antagonists Customers
9 Global PCSK9 Antagonists Analyzing Market Dynamics
- 9.1 PCSK9 Antagonists Industry Trends
- 9.2 PCSK9 Antagonists Industry Drivers
- 9.3 PCSK9 Antagonists Industry Opportunities and Challenges
- 9.4 PCSK9 Antagonists Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst